PPARG and pulmonary emphysema: Although previous studies hypothesized that PPAR gamma agonist treatments can modulate and suppress inflammation (35, 66) or even reverse CS-induced emphysema (37), our experiments have highlighted the difficulty of achieving such anti-inflammatory therapy targeting solely PPAR gamma.